A direct comparison of next generation sequencing enrichment methods using an aortopathy gene panel- clinical diagnostics perspective by Whitney L Wooderchak-Donahue et al.
Wooderchak-Donahue et al. BMC Medical Genomics 2012, 5:50
http://www.biomedcentral.com/1755-8794/5/50RESEARCH ARTICLE Open AccessA direct comparison of next generation
sequencing enrichment methods using
an aortopathy gene panel- clinical
diagnostics perspective
Whitney L Wooderchak-Donahue1†, Brendan O’Fallon1†, Larissa V Furtado2, Jacob D Durtschi1, Parker Plant1,
Perry G Ridge1, Alan F Rope3, Angela T Yetman4 and Pinar Bayrak-Toydemir1,2,5*Abstract
Background: Aortopathies are a group of disorders characterized by aneurysms, dilation, and tortuosity of the
aorta. Because of the phenotypic overlap and genetic heterogeneity of diseases featuring aortopathy, molecular
testing is often required for timely and correct diagnosis of affected individuals. In this setting next generation
sequencing (NGS) offers several advantages over traditional molecular techniques.
Methods: The purpose of our study was to compare NGS enrichment methods for a clinical assay targeting
the nine genes known to be associated with aortopathy. RainDance emulsion PCR and SureSelect RNA-bait
hybridization capture enrichment methods were directly compared by enriching DNA from eight samples.
Enriched samples were barcoded, pooled, and sequenced on the Illumina HiSeq2000 platform. Depth of coverage,
consistency of coverage across samples, and the overlap of variants identified were assessed. This data was also
compared to whole-exome sequencing data from ten individuals.
Results: Read depth was greater and less variable among samples that had been enriched using the RNA-bait
hybridization capture enrichment method. In addition, samples enriched by hybridization capture had fewer
exons with mean coverage less than 10, reducing the need for followup Sanger sequencing. Variants sets
produced were 77% concordant, with both techniques yielding similar numbers of discordant variants.
Conclusions: When comparing the design flexibility, performance, and cost of the targeted enrichment methods
to whole-exome sequencing, the RNA-bait hybridization capture enrichment gene panel offers the better
solution for interrogating the aortopathy genes in a clinical laboratory setting.
Keywords: Aortopathy, Hybridization capture, Marfan syndrome, Next generation sequencing (NGS), Target
enrichment, Emulsion PCRBackground
Aortopathies are a group of disorders characterized by
aneurysms, dilation, and tortuosity of the aorta. Thoracic
aortic aneurysm with dissection is the most common
fatal condition involving the aorta [1], and can be
syndromic, familial nonsyndromic, or sporadic. Over* Correspondence: pinar.bayrak-toydemir@aruplab.com
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distribution, and reproduction in any medium20% of thoracic aneurysms result from inherited disor-
ders [2]. Syndromic connective tissue diseases with
aortic involvment, such as Marfan syndrome (MFS;
OMIM# 154700), Loeys-Dietz syndrome (LDS; OMIM#
609192), Ehlers Danlos syndrome type IV (EDS IV;
OMIM# 130050), and congenital contractural arachno-
dactyly (OMIM# 121050) each result from mutations
in different genes yet have broadly overlapping pheno-
types [3-6]. In addition, mutations in genes related to
the structure and function of the aortic wall, including
MYH11 [7,8], ACTA2 [9], SLC2A10 [10], and NOTCH1BioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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of thoracic aortic aneurysms (reviewed in [12]).
Due to the overlapping phenotypes presented by these
disorders genetic sequencing is often required for accurate
diagnosis and appropriate clinical intervention. However,
comprehensive sequencing of the many genes involved
is often impractical with traditional Sanger methods. In
contrast, high-throughput “next-generation” sequencing
(NGS) has emerged as a new tool in the clinical laboratory
for the rapid, cost-effective detection of mutations in genes
associated with multigenic disorders [13,14]. NGS assays
targeted to a panel of genomic regions associated with
known pathogenic mutations offer several advantages over
traditional sequencing methods, including lower cost and
rapid assessment of many regions.
While NGS offers a promising alternative to Sanger
sequencing, the clinical utility of NGS methods depends
on the ability to accurately isolate or amplify the genomic
regions of interest. Ideally, the enrichment will yield high
read depths in the targeted regions while keeping errors
introduced through PCR and other sample manipula-
tions to a minimum. Several NGS target enrichment
strategies are currently available, all with various advan-
tages depending on the size of the targeted region and
the genetic targets themselves. Previous comparisons of
enrichment techniques have identified considerable differ-
ences in the depth of coverage of targeted regions as well
as the number of variants identified [15-17].
In this work we compare two competing enrichment
protocols, an emulsion-PCR based technique from
RainDance technologies [18] and a method utilizing
solution-based RNA-bait hybrid capture marketed as the
SureSelect Target Enrichment Platform [19]. Using an
aortopathy panel of nine genes (Table 1), we assess the
clinical utility of each enrichment technique. We quan-
tify the coverage of the targeted regions and compare
the accuracy and overlap of the variants identified. To
determine which molecular approach is best suited for
routine clinical diagnostics for this disorder, we also
compare read depths for the aortopathy genes generated
from the two custom-designed gene panel enrichments
to those obtained from whole-exome sequencing.
Methods
Samples
Eight samples were used to directly compare the enrich-
ment technologies. Four samples were positive controls
with a known mutation in one of the aortopathy genes
(Table 2, Samples 1–4). Samples 5 and 6 were from
patients with a clinical diagnosis of aortopathy and a
negative molecular analysis of FBN1, TGFβR1, and
TGFβR2 by Sanger sequencing analysis and multiplex
ligation-dependent probe amplification (MLPA) [20]. A
normal, healthy individual’s DNA in which a mutation inthe aortopathy genes was not expected was used as a
negative control. A Coriell sample with an FBN1
c.1888delAAinsC, p.M717X genotype was also evaluated.
This study was approved by the University of Utah
and Primary Children’s Medical Center Institutional
Review Boards (IRB#00028740). Written informed con-
sent for participation in the study was obtained from the
participants or their parents.
Emulsion PCR enrichment
A primer library (RainDance Technologies, Boston, MA)
was custom-designed to amplify 194 exons and exon/
intron boundaries for nine aortopathy genes listed in
Table 1 (~0.1 Mb). Primers were designed using Rain-
Dance’s design parameters and Primer3 (http://primer3.
sourceforge.net/). The 350 PCR amplicons ranged in size
from 201–919 bp and had a guanine cytosine (GC) con-
tent of 24-80%. Genomic DNA (1.5-3 μg) was sheared
to 2–4 kb fragments using a Covaris S2 instrument
(Covaris, Woburn, MA) and added to a mixture that
included all the components of the PCR reaction exclud-
ing the primers. This mixture and the primer library
were loaded separately onto the RDT1000 instrument,
and PCR droplets containing one primer pair per droplet
were generated. After amplification, emulsion PCR dro-
plets were broken releasing the amplicons which were
then purified and concatenated according to the manu-
facturer’s instructions. Concatenated samples were
sheared to 300 bp fragments, and Illumina adapters were
added using the SPRI-TE instrument (Beckman-Coulter,
Danvers, MA). Barcode indexes were added using PCR,
and sample quality and quantity was assessed using a
Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Solution-based hybridization capture enrichment
Custom RNA baits were designed to specifically target
the exons and exon/intron boundaries of the nine aorto-
pathy genes from Table 1 (~0.1 Mb). RNA baits were
tiled at 5 × spacing and were in replicates of 10 to in-
crease hybridization efficiency. Genomic DNA (3 μg)
was sheared to 180 bp fragments. Illumina adapters were
added using SureSelect XT kit reagents (Agilent Tech-
nologies, Santa Clara, CA). Adapter ligated DNA under-
went hybridization with the biotinylated RNA baits for
24 hours at 65°C. Hybridized DNA targets of interest
were captured using streptavidin-coated magnetic beads.
DNA targets of interest were eluted and barcode/
indexed after a series of washes to remove the non-
targeted, unbound genome. DNA quality and quantity
was assessed (Bioanalyzer).
NGS sequencing and data analysis
Concentrations of indexed samples from the enrich-
ments were determined by quantitative-PCR (KAPA
Table 1 Aortopathy panel genes
Gene name Chromosomal
locus





FBN1 15q21.1 Fibrillin Marfan syndrome 601 8616 bp 66




28a 1512 bp 9




105a 1779 bp 7
COL3A1 2q31 Collagen type III alpha 1 Ehlers Danlos Type IV 227 4401 bp 51
MYH11 16p13.13-p13.12 Myosin heavy chain 11 TAADb-patent ductus
arteriosus
3 5919 bp 41
ACTA2 10q22-q24 smooth muscle actin, alpha 2 TAAD4 syndrome 19 1134 bp 9
SLC2A10 20q13.1 solute carrier family 2 (facilitated
glucose transporter), member 10
Arterial Tortuosity
syndrome
18 1626 bp 5
NOTCH1 9q34.3 Notch homolog 1,
translocation-associated
BAV-TAAD syndrome 11 7668 bp 34
FBN2 5q23-q31 Fibrillin 2 BAV-TAAD syndrome 45 8739 bp 71
aOf the 28 patients with a TGFΒR1 mutation, 14 had Loeys-Dietz syndrome, 4 had thoracic aortic aneurysms, and 4 had Marfan-like syndrome. Of the 105 TGFΒR2
mutations, 32 had Loeys-Dietz syndrome, 31 had Marfan-like syndrome, and 8 had thoracic aortic aneurysms.
bThoracic aortic aneurysms and dissections (TAAD); Bicuspid-Aortic Valve (BAV).
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sequenced on a HiSeq2000 instrument (Illumina, San
Diego, CA) using 2 × 100 paired-end sequencing.
Sequences were aligned to the human genome reference
(hg19) sequence using the Burrows-Wheeler Alignment
tool (BWA 0.5.9) [21] with default parameters. PCR dupli-
cates were removed using the Samtools package [22], and
base quality score recalibration, local realignment, and
variant calling were performed with the Genome Analysis
Toolkit (GaTK v1.3) [23]. Variants with coverage less than
6, with 'quality-by-depth' scores of less than two, with
variant allele frequencies of less than 0.15, or with overall
quality scores of less than 10 were discarded.
Sanger sequencing
Select variants were Sanger sequenced. Primers
sequences are available upon request. Amplicons were
bi-directly sequenced using the Big DyeW Terminator
v3.1 cycle sequencing kit and an ABI 3730 DNA
Analyzer (Life Technologies, Carlsbad, CA). Sequences
were compared to reference sequences using Mutation
Surveyor (SoftGenetics, State College, PA).
Exome sequencing
In addition to the custom targeted enrichments, we also
examined depth of coverage for the targeted regions
obtained through exome sequencing. Briefly, ten samples
from individuals without known aortopathies were
sequenced on the Illumina HiSeq2000 platform after
undergoing exome capture enrichment (SureSelect
50Mb exome kit, Agilent Technologies, Santa Clara,
CA). Exome samples were indexed and pooled, two per
lane, using a one-to-one ratio, and were sequenced using
2x100-base pair paired end reads.Results
Sample enrichment
Six of eight samples underwent successful enrichment
using both RainDance emulsion PCR and SureSelect
hybridization capture (Table 2). Sample 7 (from Coriell)
failed during the RDT1000 merge when the DNA dro-
plets failed to merge properly with the primer library
droplets. Hybridization capture of this sample was also
poor and analysis was not completed due to sub-optimal
DNA quality (A260/A280 was not between 1.8 and 2.0).
Sample 8 failed during hybridization capture due to a
pipetting error. Herein, the accuracy of the two enrich-
ment methods, depth of coverage, and variant calling
were compared among the six samples enriched using
both techniques.
Accuracy
Pathogenic mutations from four positive control samples
were detected using both enrichment methods (Table 2,
samples 1–4). For example, a heterozygous FBN1
c.1585C > T, p.R529X mutation was detected in sample 1
using both enrichment methods and was confirmed
using Sanger sequencing (Additional file 1: Figure S1).
Depth of coverage
Omitting failed samples, both methods generated very
high coverage in the targeted regions. Pooling data from
all samples and examining coverage on a gene-by-gene
basis, the SureSelect enriched material yielded slightly
higher, but also more variable, coverage (per-gene aver-
age 471.7, range 189.9-592.0) compared to the emulsion
PCR technique (per-gene average 414.8, range 303.4-
554.4). Both methods yielded significantly higher aver-
age coverage per gene than whole-exome sequencing
Table 2 NGS accuracy sample results




Mean coverage Other information
1 FBN1 Positive c.1585C>T, p.R529X 101x (47%) 576x (60%) 1477x (RD) 508x (SS) In COL3A1, c.198A>G, p.I66M,
a novel change.
2 TGFBR1 Positive c.799A>G, p.N267D 317x (51%) 504x (58%) 462x (RD) 563x (SS)
3 TGFBR2 Positive c.1583G>A, p.R528H 183x (48%) 257x (50%) 177x (RD) 499x (SS)
4 MYH11 Positive IVS32+1C>A (splice) 71x (58%) 80x (50%) 140x (RD) 164x (SS)
5 Symptomatic unknown No mutations found. NA NA 33x (RD) 260x (SS) In SLC2A10 p.A206T (rs#2235491)
and p.A385G (rs#79849424).
In NOTCH1, IVS16-4C>CT (rs#3125001).
6 Symptomatic unknown COL3A1 IVS9-7T>C novel change;
potential splice site variant
48x (56%) 416x (50%) 86x (RD) 355x (SS) In COL3A1, p.A698T (rs#1800255).
In FBN2, p.V965I (rs#154001).
7 FBN1 Coriell positive Unable to confirm due to
sample quality.
Failed merge between
DNA and primer library
droplets
Poor data due to
low quality DNA
NA
8 Healthy Control No mutations found NA Failed due pipetting error 340x (RD)






















Wooderchak-Donahue et al. BMC Medical Genomics 2012, 5:50 Page 5 of 10
http://www.biomedcentral.com/1755-8794/5/50(Figure 1A) and had substantially fewer exons with less
than tenfold coverage (Figure 1B). SureSelect results
were influenced by particularly low coverage for the
NOTCH1 gene (mean 189x), a feature not observed with
the sequences generated by emulsion PCR. Low cover-
age may be related to the GC content of the NOTCH1
gene, in which 17 of 34 exons are > 65% GC.
Examining exons individuals, the SureSelect enrich-
ment yielded fewer total exons with coverage below 10
when compared to both RainDance and the whole
exome capture (Figure 1B). Some 98.5% of all exons had
mean depth greater than 50 for SureSelect, as compared
to 85.5% for RainDance and 70% for whole exome.
Despite relatively high read depths across most exons,
several exons consistently had little or no coverage
among the samples. Within the SureSelect-enchriched
sequences, much of the variation appears to be related toFigure 1 Mean depth of coverage per aortopathies gene for the enric
(SureSelect and RainDance) yielded significantly higher average coverage p
Exon Capture). Bars indicate one standard deviation. In B, the fraction of ex
shown. The custom-designed SureSelect gene panel yielded greater averag
RainDance or whole-exome enrichments.the GC content of the surrounding sequence (Figure 2).
For exons containing greater than 75% GC (for instance,
exon 1 in the NOTCH1 and TGFβR1 genes) no coverage
was observed.
In contrast to the strong correlation of GC content
with read depth for the hybridization capture enrich-
ment, exon coverage varied in an unpredictable manner
for the emulsion PCR enrichment method (Figure 3). To
assess the degree of coverage variability across samples,
we computed the standard deviation in coverage for
each exon across samples for both custom-designed
panel enrichment techniques. The mean of these devia-
tions across exons reflects the overall degree of coverage
variability across all samples, with zero indicating that
each exon was covered by the same number of reads in
every sample. Between sample variability was signifi-
cantly higher for the emulsion PCR enrichment, with ahment methods. In A, both custom-designed gene panels
er gene compared to whole-exome sequencing (SureSelect 50 Mb All
ons covered to the given depth for the enrichment methods is
e read depths across the 294 exons for all samples versus the
Figure 2 Mean exon read depth as a function of reference sequence GC content for the custom-designed gene panels. High GC content
resulted in decreased exon coverage in the SureSelect enriched samples. GC content had little to no effect on exon coverage of the RainDance
enriched samples, which were more prone to sporadic amplicon failure.
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enrichment panel (paired t-test, p < 2.2 × 10-16, Figure 4).
Variants analysis
In addition to the number of reads mapping to targeted
locations, we also assessed the quantity and character of
the variants identified by both enrichment methods. Be-
cause both methods targeted overlapping, but partially
distinct regions, we considered only those variants in the
intersection of the two capture regions. The intersection
of the two capture regions was 60.58 Kb in size, com-
prising 64% of the bases targeted by SureSelect and 99%
of bases in the RainDance capture.
In total, 252 unique variants were identified across all
samples, 195 of which were identified by both methodsFigure 3 Number of exons with mean read depth less than 20, across
represents the number of exons with low coverage for a given sample and(Additional file 1: Table S1). The sequences generated
by the RainDance enrichment contained several more
variants, 221 in total, including 26 not identified in
the SureSelect-enriched sequences. In contrast, the
SureSelect protocol yielded 214 total variants, of which
19 were not found using the emulsion PCR tech-
nique. Among the variants common to both methods,
55 (28.2%) were in dbSNP (v. 132), while 2 of the 17 var-
iants (12%) unique to SureSelect were in dbSNP, and
3 of the 23 variants (13%) unique to emulsion PCR were
in dbSNP. Assuming variants found in dbSNP are not
false positives in our samples, this suggests that even the
relatively high coverage obtained by both enrichment
methods did not guarantee accurate variant detection, as
both the custom targeted enrichment methods identifiedsamples (x-axis) and genes (y-axis). The color of the block
gene.
Figure 4 Variability in coverage: RainDance versus SureSelect.
Standard deviation in coverage for each exon across enrichment
samples was computed. The mean deviation across exons reflects
the overall degree of coverage variability across samples 1–6, with
zero indicating that each exon was covered by the same number of
reads in every sample. Between sample variability was significantly
higher for the RainDance enrichment.
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Similarly discordant results have been found in other
recent studies [13].
Examination of the discordant variants suggested sev-
eral sources for the disagreement. First, discordant var-
iants appeared in the intronic and untranslated areas at
the periphery of individual capture regions. Ten SureSe-
lect and fifteen RainDance discordant variants were
located in non-exonic regions. Examination of read
depth in these areas suggested that coverage was rela-
tively low compared to the mean for the whole exon, im-
plicating variation in read depth as a potential source of
discordant or false positive calls.
A second source of discordant variation was the
NOTCH1 gene. A relatively high fraction of the discord-
ant variants appeared in the exons of NOTCH1 (15 of
45, or 33%), and these appeared with similar frequencies
in both the RainDance and SureSelect samples (8 from
RainDance, 7 from SureSelect). NOTCH1 is likely to be
problematic for two reasons. First, the high GC content
of NOTCH1 reduces the read depths obtained with the
SureSelect enrichment procedure. Second, NOTCH1
bears substantial sequence homology to other NOTCH
genes, potentially confounding alignment algorithms and
generating spurious variant calls.
Clinical utility of the aortopathy panel
Two clinically affected individuals who had previously
tested negative for a FBN1, TGFBR1, and TGFBR2mutation by Sanger sequencing and MLPA [20] were
evaluated using the aortopathy panel. Sample 5 was from
a 19-year-old female with borderline aortic dilatation,
mild tricuspid valve prolapse and mild mitral valve insuf-
ficiency, height of 178 cm (5’10”) (99th percentile), arm
span of 176 cm (5’9”) severe pectus carinatum, scoliosis,
arachnodactyly, joint mobility, positive wrist and thumb
signs, and skin striae. Analysis of the coding region
variants and splice site variants from both enrichment
methods revealed two nonsynonymous heterozygous
variants in SLC2A10 (c.616G > A, p.Ala206Thr and
c.1154C > G, p. Ala385Gly) and a NOTCH1 potential
splice site variant (IVS16-4C > T). These variants were
present in dbSNP and are likely not disease causing.
Sample 6 was from a 34-year-old female with mild aortic
dilatation in the setting of past aortic dissection and un-
known family history. Two heterozygous nonsynonymous
variants, one in COL3A1 (c.2092G >A, p.Ala698Thr) and
the other in FBN2 (c.2893G >A, p.Val965Ile) were both
present in dbSNP, rs1800255 and rs154001 at 19.8%
and 72.4% frequencies in 1000 genomes (November 2010
release, 1000genomes.org), respectively. A novel heterozy-
gous COL3A1 variant (IVS9-7T > C) not found in dbSNP
or the COL3A1 locus specific mutation database was also
identified. Splice site prediction programs were run to
determine if the change altered splicing [24], but they pre-
dicted that no change in splicing would occur. It is likely
that this variant is also not disease causing.
No synonymous splice site variants were identified in
either patient. It is possible that these two patients have
a large deletion or duplication of one of the nine aorto-
pathy genes, but this has yet to be evaluated. Currently,
detection of structural variation cannot be reliably
detected from NGS data alone. Patient samples that test
negative from the NGS assay should be run on an exonic
level comparative genomic hybridization (CGH) array
assay used to evaluate large copy number changes in the
same gene set. Until NGS data analysis programs im-
prove in their ability and accuracy to detect structural
variation, CGH array assays are the suggested approach
for detecting such large deletions or duplications in multi-
gene panels. Alternatively, another gene not included in




All targeted enrichment methods evaluated yielded very
high read depths in the aortopathies targeted regions,
with all genes except for NOTCH1 from the exome
capture obtaining a mean depth of coverage of over 50 ×
(Figure 1). Overall, the custom-designed hybridization
capture enrichment yielded lower coverage in regions
of high GC content (Figure 2), but consistently high
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method, in contrast, yielded exons with very low cover-
age that had no obvious correlate (Figure 2). Although
influenced by GC content, the hybridization capture
nonetheless yielded fewer total exons with low coverage
than did the emulsion PCR technique (Figure 1B). Over-
all, emulsion PCR yielded significantly higher between-
sample variability in coverage. In a clinical setting, a high
degree of between sample consistency is desirable. Low
coverage exons will likely require follow-up Sanger
sequencing. Knowing which exons will require such
treatment beforehand may ameliorate the cost and add-
itional time resulting from designing new primer sets on
an as-needed basis.
Despite satisfactory coverage, the methods yielded only
partially overlapping sets of variants, with some 10% of
variants identified by one method but not by the other
(Additional file 1: Table S1). These inconsistencies may
be related to variability in read depth as well as align-
ment ambiguity related to sequence homology. Similarly
high discordancy rates were found in a recent study
comparing the RainDance and Fluidigm enrichment
platforms [13], in which only 42% of variants identified
were common to both methods, and 67% of the discord-
ant variants were found in regions of less than 20-fold
coverage. Until procedures are devised that substantially
decrease the number of regions with low coverage,
Sanger confirmation of suspected variants will likely be
necessary prior to clinical action.
A high sample failure rate of 25% (2 of 8 samples)
was observed due to sample quality (sample 7, Rain-
Dance and SureSelect) and a pipetting error (sample 8,
SureSelect) (Table 2). Based on our results, only DNA
samples of high quality (A260/280 is between 1.8 and 2.0)
should be evaluated using NGS enrichment. If a sample
falls below this initial quality measurement, DNA should
be extracted again and/or the sample should be purified
until an acceptable quality is obtained. For complex
enrichment protocols such as the SureSelect method,
pipetting errors can be avoided by incorporating auto-
mation into sample preparation (discussed further
below). This is especially important as the number of
clinical samples increase.
NGS enrichment in the clinical laboratory
When compared to emulsion PCR, the solution-based
hybridization technique yielded higher coverage as well
as greater predictability in performance. These attri-
butes, when combined with lower cost, strongly favor
the hybridization capture for enrichment of the aortopa-
thy panel in the clinical setting. Emulsion PCR enrich-
ment is significantly more expensive and requires the
use of a costly instrument. Exome sequencing is also
more costly because the cost to sequence the exome at ahigh enough depth of coverage to accurately call variants
is much higher than for the targeted panel. Samples can
also be indexed and pooled prior to hybridization capture
[25], reducing the overall cost per sample even further.
Despite the lower cost, the hybridization capture
protocol is more time consuming, complex, and labor
intensive when compared to the emulsion PCR tech-
nique. However, the ability to automate this process in
the clinical laboratory alleviates these challenges and
yields more consistent, reliable results [26]. Currently,
the emulsion PCR instrument processes one sample/hour,
limiting the total number of samples processed in a day
to approximately twenty-four. With the increasing inter-
est in exome sequencing, automation of hybridization
capture enrichment protocols have become readily avail-
able [26], and up to 96 different custom-designed NGS
panels and exome hybridizations can take place at the
same time during the same run. Solution-based hybridi-
zation libraries can be ordered in larger volumes, ali-
quoted for up to two-three freeze/thaw cycles, and stored
for up to one year. RainDance primer libraries have to be
switched out after the eighth sample with the RDT1000
instrument design, and if there are not eight samples to
run using the same primer library, the rest will be wasted.
Conclusions
The aortopathy panel offers a cost-effective, faster mo-
lecular diagnostic assay compared to the conventional
gene-by-gene Sanger sequencing approach. Both Rain-
Dance and SureSelect enrichment methods accurately
identified variants in the positive samples assayed, and
overall coverage was high across most exons for all sam-
ples. Hybrid capture results demonstrated that genes with
high homology to other genes and high GC rich regions
can be problematic. However, we note that increases in
read length, currently available with the Ion Torrent or
Illumina MiSeq instruments, are likely to alleviate
homology-related alignment issues. After comparing the
cost, design flexibility, and versatility of the workflows of
the two enrichment methods, the custom-designed
hybridization capture design offers the best solution for
enriching the aortopathy genes in a clinical laboratory set-
ting. Patients with Marfan syndrome and Marfan-like syn-
dromes featuring aortopathies will benefit from the timely
molecular diagnosis of this new testing approach which
will lead to the appropriate surveillance and interventions
aimed at preventing the significant morbidity and mortal-
ity associated with these conditions.
Additional file
Additional file 1: Figure S1. NGS and Sanger sequencing confirm the
pathogenic FBN1 mutation in sample 1. A heterozygous nonsense
mutation (c.1585C>T, p.R529X) was detected using RainDance PCR
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http://www.biomedcentral.com/1755-8794/5/50enrichment (panel A) and SureSelect capture enrichment (panel B). In C,
Sanger sequencing confirmed the mutation detected in both enrichment
strategies. The FBN1 gene is on the reverse strand, and appears in the 3’
to 5’ orientation in the NGS traces versus the Sanger sequencing trace
which is 5’ to 3’. Table S1. Summary of variants detected from the
RainDance and SureSelect enrichments.
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